← FDA DRUG APPROVALS

FDA ANDA · ANDA216807

OCTREOTIDE ACETATE

Sponsor: GLAND

APPLICATION
ANDA216807
TYPE
ANDA
ORIGINAL APPROVAL
2023-06-13
LATEST ACTION
2024-09-30
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OCTREOTIDE ACETATEPrescription
OCTREOTIDE ACETATE EQ 1MG BASE/ML · INJECTABLE · INJECTION
OCTREOTIDE ACETATEPrescription
OCTREOTIDE ACETATE EQ 0.2MG BASE/ML · INJECTABLE · INJECTION

Approval history

2024-09-30Labeling · Supplement 2 · standardAP
2024-06-14Labeling · Supplement 1 · standardAP
2023-06-13UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →